Trial Profile
Randomised clinical trial to evaluate ACUITY bleeding rates in ST elevation myocardial infarction (STEMI) patients undergoing rescue percutaneous coronary intervention (PCI) post failed fibrinolysis, treated with bivalirudin or heparin and a glycoprotein IIb/IIIa inhibitor
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary) ; Abciximab; Eptifibatide; Heparin; Tirofiban
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Adverse reactions
- Acronyms RESCUE-PCI
- Sponsors Novartis Pharma A.G.
- 17 Nov 2021 Status changed from completed to discontinued.
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 25 Jul 2011 New trial record